Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""ANTINEOPLASTIC agents"" wg kryterium: Temat


Starter badań:

Tytuł :
Pharmacological profile and effects of mitotane in adrenocortical carcinoma.
Autorzy :
Corso CR; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil.; Faculdades Pequeno Príncipe, Curitiba, Brazil.
Acco A; Pharmacology Department, Federal University of Paraná, Curitiba, Brazil.
Bach C; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil.; Faculdades Pequeno Príncipe, Curitiba, Brazil.
Bonatto SJR; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil.; Faculdades Pequeno Príncipe, Curitiba, Brazil.
de Figueiredo BC; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil.; Faculdades Pequeno Príncipe, Curitiba, Brazil.
de Souza LM; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil.; Faculdades Pequeno Príncipe, Curitiba, Brazil.
Pokaż więcej
Źródło :
British journal of clinical pharmacology [Br J Clin Pharmacol] 2021 Jul; Vol. 87 (7), pp. 2698-2710. Date of Electronic Publication: 2021 Feb 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Adrenal Cortex Neoplasms*/drug therapy
Adrenocortical Carcinoma*/drug therapy
Antineoplastic Agents*/therapeutic use
Antineoplastic Agents, Hormonal/pharmacology ; Antineoplastic Agents, Hormonal/therapeutic use ; Humans ; Mitotane/therapeutic use ; Steroids
Czasopismo naukowe
Tytuł :
Impact of COVID-19 Pandemic on Surgical Breast Cancer Patients Undergoing Neoadjuvant Therapy: A Multicentric Study.
Autorzy :
Vanni G; Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Pellicciaro M; Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy; .
Combi F; Division of Breast Surgical Oncology Department of Medical and Surgery, Maternal-infantile and Adult Sciences, University Hospital of Modena and Reggio Emilila, Modena, Italy.
Papi S; Division of Breast Surgical Oncology Department of Medical and Surgery, Maternal-infantile and Adult Sciences, University Hospital of Modena and Reggio Emilila, Modena, Italy.
Materazzo M; Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Segattini S; Division of Breast Surgical Oncology Department of Medical and Surgery, Maternal-infantile and Adult Sciences, University Hospital of Modena and Reggio Emilila, Modena, Italy.
Rizza S; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Chiocchi M; Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, University of Rome, Rome, Italy.
Perretta T; Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, University of Rome, Rome, Italy.
Meucci R; Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, University of Rome, Rome, Italy.
Portarena I; Department of Oncology, Policlinico Tor Vergata University, Rome, Italy.
Pistolese CA; Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, University of Rome, Rome, Italy.
Ielpo B; Unidad de Chirugia Hepatobiliopancreática, Hospital Universitario del Mar, Barcelona, Spain.
Campanelli M; Emergency Surgery Unit, University Hospital of Tor Vergata, Rome, Italy.
Lisi G; Department of Surgery, Sant'Eugenio Hospital, Rome, Italy.
Chiaravalloti A; Department of Biomedicine and Prevention, Policlinico Tor Vergata University, Rome, Italy.; IRCCS Neuromed, UOC Medicina Nucleare, Pozzilli, Italy.
Tazzioli G; Division of Breast Surgical Oncology Department of Medical and Surgery, Maternal-infantile and Adult Sciences, University Hospital of Modena and Reggio Emilila, Modena, Italy.
Buonomo OC; Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Sep; Vol. 41 (9), pp. 4535-4542.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Breast Neoplasms/*drug therapy
Breast Neoplasms/*surgery
COVID-19/*epidemiology
Mammaplasty/*statistics & numerical data
Neoadjuvant Therapy/*statistics & numerical data
Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents, Hormonal/administration & dosage ; Antineoplastic Agents, Hormonal/adverse effects ; COVID-19/complications ; Drug Therapy/statistics & numerical data ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; Pandemics ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Cutaneous adverse events in patients receiving anticancer therapy in a tertiary hospital setting: the old and the new.
Autorzy :
Suh HJ; Dermatology Department, Pontevedra University Hospital, Pontevedra, Spain.
Flórez Á; Dermatology Department, Pontevedra University Hospital, Pontevedra, Spain.
Sacristán V; Medical Oncology Department, A Coruña University Hospital, A Coruña, Spain.
Rodríguez Martinez Á; Medical Oncology Department, Pontevedra University Hospital, Pontevedra, Spain.
Fernández F; Pharmacy Department, Pontevedra University Hospital, Pontevedra, Spain.
Vilanova-Trillo L; Dermatology Department, Pontevedra University Hospital, Pontevedra, Spain.
Constenla M; Medical Oncology Department, Pontevedra University Hospital, Pontevedra, Spain.
Pereiro M; Surgical Medical Specialties Department, Dermatology Section, Santiago de Compostela University, Santiago de Compostela, Spain.
Pokaż więcej
Źródło :
International journal of dermatology [Int J Dermatol] 2021 Feb; Vol. 60 (2), pp. 208-216. Date of Electronic Publication: 2020 Aug 09.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Antineoplastic Agents*/adverse effects
Drug Eruptions*/etiology
Aged ; Antineoplastic Agents, Immunological/adverse effects ; Cross-Sectional Studies ; Female ; Humans ; Immunotherapy/adverse effects ; Male ; Middle Aged ; Quality of Life ; Tertiary Care Centers
Czasopismo naukowe
Tytuł :
Medication Errors During Treatment with New Oral Anticancer Agents: Consequences for Clinical Practice Based on the AMBORA Study.
Autorzy :
Schlichtig K; Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Erlangen, Germany.
Dürr P; Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Erlangen, Germany.; Pharmacy Department, Erlangen University Hospital, Erlangen, Germany.
Dörje F; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Erlangen, Germany.; Pharmacy Department, Erlangen University Hospital, Erlangen, Germany.
Fromm MF; Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Erlangen, Germany.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Oct; Vol. 110 (4), pp. 1075-1086. Date of Electronic Publication: 2021 Jul 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Interactions*
Food-Drug Interactions*
Polypharmacy*
Antineoplastic Agents/*therapeutic use
Medication Errors/*statistics & numerical data
Neoplasms/*drug therapy
Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Analgesics/therapeutic use ; Anti-Ulcer Agents/therapeutic use ; Antihypertensive Agents/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use ; Comorbidity ; Coronary Disease/drug therapy ; Coronary Disease/epidemiology ; Decision Support Systems, Clinical ; Diabetes Mellitus/drug therapy ; Diabetes Mellitus/epidemiology ; Dyslipidemias/drug therapy ; Dyslipidemias/epidemiology ; Female ; Fibrinolytic Agents/therapeutic use ; Humans ; Hypertension/drug therapy ; Hypertension/epidemiology ; Hypolipidemic Agents/therapeutic use ; Hypothyroidism/drug therapy ; Hypothyroidism/epidemiology ; Male ; Middle Aged ; Protein Kinase Inhibitors/therapeutic use ; Thyroid Hormones/therapeutic use ; Vitamins/therapeutic use
Czasopismo naukowe
Tytuł :
Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma.
Autorzy :
Guo L; Department of Infection, Qingdao No. 6 People's Hospital, Qingdao 266033, PR China.
Li H; Department of Dermatology, Qingdao No. 6 People's Hospital, Qingdao 266033, PR China.
Fan T; Department of Infection, Qingdao No. 6 People's Hospital, Qingdao 266033, PR China.
Ma Y; Department of Infection, Qingdao No. 6 People's Hospital, Qingdao 266033, PR China. Electronic address: .
Wang L; Department of Hepatology, Qingdao No. 6 People's Hospital, Qingdao 266033, PR China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2021 Aug 15; Vol. 279, pp. 119359. Date of Electronic Publication: 2021 Mar 19.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Synergism*
Antineoplastic Agents, Immunological/*pharmacology
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Carcinoma, Hepatocellular/*drug therapy
Curcumin/*pharmacology
Liver Neoplasms/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Animals ; Antineoplastic Agents/pharmacology ; Apoptosis ; Carcinoma, Hepatocellular/metabolism ; Carcinoma, Hepatocellular/pathology ; Cell Proliferation ; E1A-Associated p300 Protein/genetics ; E1A-Associated p300 Protein/metabolism ; Female ; Humans ; Leukocytes, Mononuclear/drug effects ; Leukocytes, Mononuclear/metabolism ; Liver Neoplasms/metabolism ; Liver Neoplasms/pathology ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Transforming Growth Factor beta1/genetics ; Transforming Growth Factor beta1/metabolism ; Tumor Cells, Cultured ; Tumor Microenvironment ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Autorzy :
Yao H; Department of Neurosurgery, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215007, Jiangsu, China.
Liu J; Department of Neurosurgery, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215007, Jiangsu, China.
Zhang C; Department of Neurosurgery, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215007, Jiangsu, China.
Shao Y; Department of Neurosurgery, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215007, Jiangsu, China.
Li X; Department of Neurosurgery, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215007, Jiangsu, China.
Feng M; Department of Neurosurgery, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215007, Jiangsu, China.
Wang X; Department of Radiologly, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215007, Jiangsu, China.
Gan W; Department of Pathology, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215007, Jiangsu, China.
Zhou Y; Department of Neurosurgery, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215007, Jiangsu, China. Electronic address: .
Huang Y; Department of Neurosurgery, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215007, Jiangsu, China. Electronic address: .
Pokaż więcej
Źródło :
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia [J Clin Neurosci] 2021 Aug; Vol. 90, pp. 82-88. Date of Electronic Publication: 2021 Jun 05.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Brain Neoplasms/*drug therapy
Glioma/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Pyridines/*therapeutic use
Temozolomide/*therapeutic use
Adolescent ; Adult ; Aged ; Antineoplastic Agents, Alkylating/therapeutic use ; Brain Neoplasms/mortality ; Brain Neoplasms/pathology ; Drug Therapy, Combination ; Female ; Glioma/mortality ; Glioma/pathology ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Quality of Life ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Synergistic Cytotoxic and Apoptotic Effects of Local Probiotic Lactobacillus Brevis Isolated from Regional Dairy Products in Combination with Tamoxifen.
Autorzy :
Nasiri Z; Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Montazeri H; School of Pharmacy-International Campus, Iran University of Medical Sciences, Tehran, Iran.
Akbari N; Department of Microbiology, Faculty of Science, Islamic Azad University, Arak, Iran.
Mirfazli SS; Department of Medical Chemistry, School of Pharmacy- International Campus, Iran University of Medical Sciences, Tehran, Iran.
Tarighi P; Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło :
Nutrition and cancer [Nutr Cancer] 2021; Vol. 73 (2), pp. 290-299. Date of Electronic Publication: 2020 May 25.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents*/pharmacology
Breast Neoplasms*/drug therapy
Lactobacillus brevis*
Probiotics*
Antineoplastic Agents, Hormonal/pharmacology ; Antineoplastic Agents, Hormonal/therapeutic use ; Apoptosis ; Cell Line, Tumor ; Dairy Products ; Female ; Humans ; Tamoxifen/pharmacology
Czasopismo naukowe
Tytuł :
Flavokawain C exhibits anti-tumor effects on in vivo HCT 116 xenograft and identification of its apoptosis-linked serum biomarkers via proteomic analysis.
Autorzy :
Phang CW; Institute of Biological Sciences, Faculty of Science, Universiti Malaya, 50603, Kuala Lumpur, Malaysia. Electronic address: .
Abd Malek SN; Institute of Biological Sciences, Faculty of Science, Universiti Malaya, 50603, Kuala Lumpur, Malaysia. Electronic address: .
Karsani SA; Institute of Biological Sciences, Faculty of Science, Universiti Malaya, 50603, Kuala Lumpur, Malaysia; Universiti Malaya Centre for Proteomics Research (UMCPR), Universiti Malaya, 50603, Kuala Lumpur, Malaysia. Electronic address: .
Pokaż więcej
Źródło :
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2021 May; Vol. 137, pp. 110846. Date of Electronic Publication: 2021 Feb 20.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Phytogenic/*pharmacology
Apoptosis/*drug effects
Apoptosis/*genetics
Apoptosis Regulatory Proteins/*genetics
Chalcones/*pharmacology
Colonic Neoplasms/*drug therapy
Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents, Phytogenic/adverse effects ; Antineoplastic Agents, Phytogenic/therapeutic use ; Biomarkers/blood ; Body Weight/drug effects ; Caspase 3/metabolism ; Cell Proliferation/drug effects ; Chalcones/adverse effects ; Chalcones/therapeutic use ; Cisplatin/pharmacology ; Female ; HCT116 Cells ; Humans ; Kava/chemistry ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Proteomics/methods ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials.
Autorzy :
Reuss JE; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
Stern D; Yale New Haven Health System, Bridgeport, Connecticut.
Foster JC; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
Ramaswami R; HIV/AIDS Malignancy Branch, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland.
Lurain K; HIV/AIDS Malignancy Branch, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland.
Chen HX; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Streicher H; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Kem R; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Little RF; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Sharon E; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Pokaż więcej
Źródło :
JAMA network open [JAMA Netw Open] 2020 Dec 01; Vol. 3 (12), pp. e2027110. Date of Electronic Publication: 2020 Dec 01.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents*/therapeutic use
Patient Selection*
B7-H1 Antigen/*therapeutic use
Clinical Trials as Topic/*methods
HIV Infections/*drug therapy
Neoplasms/*drug therapy
Programmed Cell Death 1 Receptor/*therapeutic use
Antineoplastic Agents, Immunological ; HIV Infections/blood ; Humans ; Immune Checkpoint Inhibitors ; Program Evaluation
Czasopismo naukowe
Tytuł :
Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemic.
Autorzy :
Oo C; CO-SunLife Biopharma, NJ, USA; BA-Rutgers Robert Wood Johnson Medical School, NJ, USA. Electronic address: .
Ameer B; CO-SunLife Biopharma, NJ, USA; BA-Rutgers Robert Wood Johnson Medical School, NJ, USA.
Pokaż więcej
Źródło :
Drug discovery today [Drug Discov Today] 2021 Jun; Vol. 26 (6), pp. 1337-1339. Date of Electronic Publication: 2021 Apr 29.
Typ publikacji :
Editorial
MeSH Terms :
Drug Development*/organization & administration
Drug Development*/trends
Medical Oncology*/methods
Medical Oncology*/trends
Antineoplastic Agents, Immunological/*pharmacology
COVID-19/*epidemiology
Immune Checkpoint Inhibitors/*pharmacology
Immunoconjugates/*pharmacology
Neoplasms/*drug therapy
Antineoplastic Agents/pharmacology ; Drug Approval ; Humans ; Molecular Targeted Therapy/methods ; SARS-CoV-2 ; United States
Opinia redakcyjna
Tytuł :
Premature ovarian failure after childhood cancer and risk of metabolic syndrome: a cross-sectional analysis.
Autorzy :
Netterlid A; Department of Pediatrics, Helsingborg Hospital, Lund University, Helsingborg, Sweden.
Mörse H; Department of Pediatrics, Pediatric Oncology and Hematology, Skåne University Hospital, Lund University, Lund, Sweden.
Giwercman A; Department of Reproductive Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.
Henic E; Department of Reproductive Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.
Åkesson KE; Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö, Sweden.
Erfurth EM; Department of Endocrinology, Pediatric Endocrinology, Skåne University Hospital, Lund University, Lund, Sweden.
Elfving M; Department of Pediatrics, Pediatric Endocrinology, Skåne University Hospital, Lund University, Lund, Sweden.
Pokaż więcej
Źródło :
European journal of endocrinology [Eur J Endocrinol] 2021 May 21; Vol. 185 (1), pp. 67-75. Date of Electronic Publication: 2021 May 21.
Typ publikacji :
Journal Article
MeSH Terms :
Cancer Survivors*
Antineoplastic Agents/*therapeutic use
Metabolic Syndrome/*epidemiology
Neoplasms/*therapy
Primary Ovarian Insufficiency/*epidemiology
Radiotherapy/*methods
Absorptiometry, Photon ; Adipose Tissue ; Adult ; Anti-Mullerian Hormone/blood ; Antineoplastic Agents, Alkylating/therapeutic use ; Blood Glucose/metabolism ; Body Composition ; Case-Control Studies ; Cholesterol/blood ; Cholesterol, HDL/blood ; Cholesterol, LDL/blood ; Female ; Glycated Hemoglobin A/metabolism ; Humans ; Insulin/blood ; Metabolic Syndrome/metabolism ; Middle Aged ; Primary Ovarian Insufficiency/metabolism ; Risk Factors ; Triglycerides/blood ; Young Adult
Czasopismo naukowe
Tytuł :
Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatment in Italy.
Autorzy :
Aschele C; Medical Oncology Unit, Department of Oncology, Ospedale Sant'Andrea, La Spezia, Italy.
Negru ME; Medical Oncology Unit, Department of Oncology, Ospedale Sant'Andrea, La Spezia, Italy.
Pastorino A; Medical Oncology Unit, Department of Oncology, Ospedale Sant'Andrea, La Spezia, Italy.
Cavanna L; Department of Oncology-Hematology, G. da Saliceto Hospital, Piacenza, Italy.
Zagonel V; Oncology Unit 1, Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy.
Barone-Adesi F; Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.; CRIMEDIM - Research Center in Emergency and Disaster Medicine, Università del Piemonte Orientale, Novara, Italy.
Blasi L; Medical Oncology Unit, Ospedale Civico, Arnas, Palermo.
Pokaż więcej
Źródło :
JAMA oncology [JAMA Oncol] 2021 Feb 01; Vol. 7 (2), pp. 304-306.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
COVID-19/*epidemiology
Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Hormonal/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/epidemiology ; COVID-19/physiopathology ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/epidemiology ; Female ; Hospitalization ; Humans ; Immunotherapy ; Italy/epidemiology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/epidemiology ; Male ; Middle Aged ; Molecular Targeted Therapy ; Neoplasms/epidemiology ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/epidemiology ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide.
Autorzy :
Ebrahimi Zade A; Faculty of Industrial Engineering and Systems Management, Amirkabir University of Technology, Tehran, Iran.
Shahabi Haghighi S; Faculty of Industrial Engineering and Systems Management, Amirkabir University of Technology, Tehran, Iran. Electronic address: .
Soltani M; Faculty of Mechanical Engineering, K.N. Toosi University of Technology, Tehran 1969764499, Iran; Advanced Bioengineering Initiative Center, Computational Medicine Center, K. N. Toosi University of Technology, Tehran, Iran; Centre for Biotechnology and Bioengineering (CBB), University of Waterloo, Waterloo, ON, Canada; Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, ON, Canada.
Pokaż więcej
Źródło :
Computer methods and programs in biomedicine [Comput Methods Programs Biomed] 2020 Sep; Vol. 193, pp. 105443. Date of Electronic Publication: 2020 Mar 19.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents*/therapeutic use
Brain Neoplasms*/drug therapy
Glioblastoma*/drug therapy
Adult ; Antineoplastic Agents, Alkylating/therapeutic use ; Cell Line, Tumor ; Humans ; Temozolomide/therapeutic use
Czasopismo naukowe
Tytuł :
Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer.
Autorzy :
Ogino M; Division of Breast and Endocrine Surgery, and.; Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.; Department of Breast and Endocrine Surgery, National Hospital Organization Takasaki General Medical Center, Gunma, Japan.
Fujii T; Division of Breast and Endocrine Surgery, and .; Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.
Koibuchi Y; Department of Breast and Endocrine Surgery, National Hospital Organization Takasaki General Medical Center, Gunma, Japan.
Nakazawa Y; Division of Breast and Endocrine Surgery, and.; Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.
Takata D; Department of Breast and Endocrine Surgery, National Hospital Organization Takasaki General Medical Center, Gunma, Japan.
Shirabe K; Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Aug; Vol. 41 (8), pp. 3899-3904.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Albumins/*therapeutic use
Antineoplastic Agents, Alkylating/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Antineoplastic Agents, Phytogenic/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*drug therapy
Cyclophosphamide/*therapeutic use
Paclitaxel/*therapeutic use
Trastuzumab/*therapeutic use
Adult ; Aged ; Albumins/adverse effects ; Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Phytogenic/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Breast Neoplasms/mortality ; Cyclophosphamide/adverse effects ; Female ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoadjuvant Therapy ; Paclitaxel/adverse effects ; Receptor, ErbB-2 ; Trastuzumab/adverse effects
Czasopismo naukowe
Tytuł :
EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer.
Autorzy :
Liu X; Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA.
Adorno-Cruz V; Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.; Department of Pharmacology, Case Western Reserve University, Cleveland, OH, USA.
Chang YF; The Ben May Department for Cancer Research, the University of Chicago, Chicago, IL, USA.
Jia Y; Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Kawaguchi M; Laboratory of Functional Biology, Graduate School of Biostudies, Kyoto University, Kyoto, Japan.
Dashzeveg NK; Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Taftaf R; Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.; Drikskill Graduate Program in Life Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Ramos EK; Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.; Drikskill Graduate Program in Life Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Schuster EJ; Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.; Drikskill Graduate Program in Life Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
El-Shennawy L; Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Patel D; Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Zhang Y; Department of Medicine, the Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Cristofanilli M; Department of Medicine, the Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Liu H; Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.; Department of Medicine, the Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.; Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.; Department of Pathology and Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Pokaż więcej
Źródło :
Theranostics [Theranostics] 2021 Apr 30; Vol. 11 (13), pp. 6632-6643. Date of Electronic Publication: 2021 Apr 30 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Molecular Targeted Therapy*
Antineoplastic Agents, Immunological/*therapeutic use
Cell Aggregation/*drug effects
Lung Neoplasms/*secondary
Neoplasm Proteins/*antagonists & inhibitors
Neoplastic Stem Cells/*drug effects
Triple Negative Breast Neoplasms/*drug therapy
Animals ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/immunology ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/immunology ; ErbB Receptors/physiology ; Erlotinib Hydrochloride/therapeutic use ; Female ; Genes, Reporter ; Humans ; Hyaluronan Receptors/antagonists & inhibitors ; Hyaluronan Receptors/physiology ; Lung Neoplasms/prevention & control ; Mice ; MicroRNAs/genetics ; Neoplasm Proteins/physiology ; Neoplastic Cells, Circulating/drug effects ; RNA/genetics ; Triple Negative Breast Neoplasms/pathology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
Autorzy :
da Cunha-Bang C; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Rostgaard K; Department of Epidemiology Research, Statens Serum Institut - SSI, Copenhagen, Denmark.
Andersen MA; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Epidemiology Research, Statens Serum Institut - SSI, Copenhagen, Denmark.
Rotbain EC; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Hematology, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Grønbaek K; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
Frederiksen H; Department of Hematology, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Hjalgrim H; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Epidemiology Research, Statens Serum Institut - SSI, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2021 Apr; Vol. 193 (2), pp. 339-345. Date of Electronic Publication: 2021 Feb 11.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*adverse effects
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Myelodysplastic Syndromes/*chemically induced
Neoplasms, Second Primary/*chemically induced
Aged ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Alkylating/therapeutic use ; Bendamustine Hydrochloride/adverse effects ; Bendamustine Hydrochloride/therapeutic use ; Chlorambucil/adverse effects ; Chlorambucil/therapeutic use ; Cohort Studies ; Denmark/epidemiology ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/complications ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Male ; Myelodysplastic Syndromes/epidemiology ; Neoplasms, Second Primary/epidemiology ; Neoplasms, Second Primary/pathology ; Registries ; Risk Assessment ; Survival Analysis ; Vidarabine/adverse effects ; Vidarabine/analogs & derivatives ; Vidarabine/therapeutic use
Czasopismo naukowe
Tytuł :
Amomum subulatum Induces Apoptosis in Tumor Cells and Reduces Tumor Burden in Experimental Animals via Modulating Pro-Inflammatory Cytokines.
Autorzy :
Sudarsanan D; Laboratory of Immunopharmacology and Experimental Therapeutics, Division of Cancer Research, Regional Cancer Centre Medical College Campus (Research Centre, University of Kerala), Thiruvananthapuram, Kerala, India.
Suresh Sulekha D; Laboratory of Immunopharmacology and Experimental Therapeutics, Division of Cancer Research, Regional Cancer Centre Medical College Campus (Research Centre, University of Kerala), Thiruvananthapuram, Kerala, India.
Chandrasekharan G; Laboratory of Immunopharmacology and Experimental Therapeutics, Division of Cancer Research, Regional Cancer Centre Medical College Campus (Research Centre, University of Kerala), Thiruvananthapuram, Kerala, India.
Pokaż więcej
Źródło :
Cancer investigation [Cancer Invest] 2021 Apr; Vol. 39 (4), pp. 333-348. Date of Electronic Publication: 2021 Feb 01.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Amomum*/chemistry
Antineoplastic Agents, Phytogenic/*pharmacology
Apoptosis/*drug effects
Ascites/*drug therapy
Lymphoma, T-Cell/*drug therapy
Plant Extracts/*pharmacology
Animals ; Antineoplastic Agents, Alkylating/pharmacology ; Antineoplastic Agents, Phytogenic/isolation & purification ; Ascites/blood ; Ascites/pathology ; Cell Line, Tumor ; Cyclophosphamide/pharmacology ; Cytokines/blood ; Inflammation Mediators/blood ; Inflammation Mediators/metabolism ; Lymphoma, T-Cell/blood ; Lymphoma, T-Cell/pathology ; Male ; Mice, Inbred BALB C ; Plant Extracts/isolation & purification ; Signal Transduction ; Tumor Burden/drug effects
Czasopismo naukowe
Tytuł :
Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer.
Autorzy :
Enomoto T; Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan. .
Tamiya A; Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan.
Matsumoto K; Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan.
Adachi Y; Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan.
Azuma K; Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan.
Inagaki Y; Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan.
Kouno S; Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan.
Taniguchi Y; Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan.
Saijo N; Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan.
Okishio K; Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan.
Atagi S; Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan.
Pokaż więcej
Źródło :
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2021 Mar; Vol. 23 (3), pp. 582-590. Date of Electronic Publication: 2020 Jul 13.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Immune Checkpoint Inhibitors/*therapeutic use
Lung Neoplasms/*drug therapy
Nivolumab/*therapeutic use
Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/adverse effects ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Cross-Sectional Studies ; Disease Progression ; Drug Substitution/statistics & numerical data ; Female ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Kaplan-Meier Estimate ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Nivolumab/adverse effects ; Regression Analysis ; Response Evaluation Criteria in Solid Tumors ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
Autorzy :
Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Janssens A; Universitaire Ziekenhuizen Leuven, Leuven, Belgium.
Gritti G; Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Radford J; Department of Medical Oncology, University of Manchester, Manchester, United Kingdom.; The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
Timmerman J; Division of Hematology & Oncology, University of California Los Angeles, Los Angeles, CA.
Pinto A; Istituto Nazionale Tumori, Fondazione Pascale, Istituto di Ricovero e Cura a Carattere Scientifico, Naples, Italy.
Mercadal Vilchez S; Institut Català d'Oncologia-Duran y Reynals, Hospitalet de Llobregat, Barcelona, Spain.
Johnson P; Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom.; NIHR/CRUK Experimental Cancer Medicine Centre, Southampton, United Kingdom.
Cunningham D; The Royal Marsden Hospital, Surrey, United Kingdom.
Leonard JP; Weill Cornell Medicine, New York, NY.; New York Presbyterian Hospital, New York, NY.
Rodig SJ; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA.
Martín-Regueira P; Bristol Myers Squibb, Princeton, NJ; and.
Sumbul A; Bristol Myers Squibb, Princeton, NJ; and.
Samakoglu S; Bristol Myers Squibb, Princeton, NJ; and.
Tang H; Bristol Myers Squibb, Princeton, NJ; and.
Ansell SM; Mayo Clinic, Rochester, MN.
Pokaż więcej
Źródło :
Blood [Blood] 2021 Feb 04; Vol. 137 (5), pp. 637-645.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Salvage Therapy*
Antineoplastic Agents, Immunological/*therapeutic use
Lymphoma, Follicular/*drug therapy
Nivolumab/*therapeutic use
Adult ; Aged ; Antineoplastic Agents, Alkylating/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor ; Female ; Follow-Up Studies ; Gene Expression Profiling ; Humans ; Kaplan-Meier Estimate ; Lymphoma, Follicular/diagnostic imaging ; Male ; Middle Aged ; Neoplasm Proteins/antagonists & inhibitors ; Nivolumab/adverse effects ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Progression-Free Survival ; Recurrence ; Rituximab/administration & dosage ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
Autorzy :
Merino M; Department of Pharmaceutical Technology and Chemistry, School of Pharmacy, University of Navarra, 31008, Pamplona, Navarra, Spain.
Lozano T; Program of Immunology and Immunotherapy, CIMA-Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdisNA), Pamplona, Spain.
Casares N; Program of Immunology and Immunotherapy, CIMA-Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdisNA), Pamplona, Spain.
Lana H; Department of Pharmaceutical Technology and Chemistry, School of Pharmacy, University of Navarra, 31008, Pamplona, Navarra, Spain.
Troconiz IF; Department of Pharmaceutical Technology and Chemistry, School of Pharmacy, University of Navarra, 31008, Pamplona, Navarra, Spain.; Navarra Institute for Health Research (IdisNA), Pamplona, Spain.
Ten Hagen TLM; Laboratory of Experimental Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.
Kochan G; Navarra Institute for Health Research (IdisNA), Pamplona, Spain.; Department of Oncology, Navarrabiomed-Biomedical Research Centre, Pamplona, Spain.
Berraondo P; Program of Immunology and Immunotherapy, CIMA-Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdisNA), Pamplona, Spain.
Zalba S; Department of Pharmaceutical Technology and Chemistry, School of Pharmacy, University of Navarra, 31008, Pamplona, Navarra, Spain. .; Navarra Institute for Health Research (IdisNA), Pamplona, Spain. .
Garrido MJ; Department of Pharmaceutical Technology and Chemistry, School of Pharmacy, University of Navarra, 31008, Pamplona, Navarra, Spain. .; Navarra Institute for Health Research (IdisNA), Pamplona, Spain. .
Pokaż więcej
Źródło :
Journal of nanobiotechnology [J Nanobiotechnology] 2021 Apr 13; Vol. 19 (1), pp. 102. Date of Electronic Publication: 2021 Apr 13.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
B7-H1 Antigen/*metabolism
Doxorubicin/*pharmacology
Immunity/*drug effects
Liposomes/*immunology
Melanoma/*drug therapy
Animals ; Antibodies, Monoclonal/pharmacology ; Antineoplastic Agents, Immunological/pharmacology ; Cell Line, Tumor ; Disease Models, Animal ; Drug Liberation ; Drug Therapy ; Female ; Immunotherapy/methods ; Melanoma, Experimental/drug therapy ; Mice ; Mice, Inbred C57BL
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies